July 16th 2024
Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Zolbetuximab/Chemo Up Front Yields Benefit in CLDN18.2+ Advanced Gastric/GEJ Cancer
January 20th 2023Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.
Ghassan K. Abou-Alfa, MD, Discusses Next Steps in Researching Unresectable HCC
November 23rd 2022Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Ghassan K. Abou-Alfa, MD, Highlights Approval of Tremelimumab and Durvalumab in Unresectable HCC
October 31st 2022Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
First-Line Tremelimumab ± Durvalumab Misses ORR End Point in Biliary Tract Cancer
September 30th 2022Results from the phase 2 IMMUCHEC trial indicated that tremelimumab with or without durvalumab did not meet the primary end point of improved objective response rate vs chemotherapy in patients with treatment-naïve biliary tract cancer.
Clinical Benefit of Trastuzumab Deruxtecan Sustained in Metastatic Gastric/GEJ Cancer
September 10th 2022Long-term follow-up of the phase 2 DESTINY-Gastric02 study revealed fam-trastuzumab deruxtecan-nxki continues to show promise in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Tislelizumab Plus Chemo Yields Survival Benefit Vs Chemo in Advanced ESCC
July 7th 2022The phase 3 RATIONALE 306 trial showed improved overall survival for patients receiving tislelizumab plus chemotherapy vs placebo and chemotherapy for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status.
IMU-131 Plus SOC Improves OS Vs SOC Alone in Advanced/Metastatic Gastric or GEJ Cancer
June 28th 2022Results from the phase 2 HERIZON study identified improved overall survival for patients treated with IMU-131 plus standard of care vs standard of care alone in advanced or metastatic gastric or gastroesophageal junction cancer.